HumaninWhat the studies show

In the 2001 experiments, cultured neurons were killed by three different mutant genes that cause familial Alzheimer's disease and by the amyloid-beta peptide, and humanin added to the medium kept them alive in every case; swapping one serine for a glycine, the analogue called HNG, made it about a thousand times more potent ¹. Two years later a group in California found a mechanism that reaches beyond the brain: humanin binds Bax, the protein that punches holes in mitochondria to start programmed cell death, and keeps it from reaching the mitochondrial membrane ⁴. That makes humanin a general brake on one of the main routes to cell suicide, which is why it has since been studied in heart, kidney, blood vessels and the retina.

In 2009 a group at the Albert Einstein College of Medicine infused humanin and its potent analogue into rats and measured insulin action with the clamp technique that is the standard for the question. The peptide made the animals more sensitive to insulin: the liver produced less glucose and muscle took up more, and the effect ran through the hypothalamus rather than through the tissues directly, since blocking the signal in the brain removed it ⁵. The same paper reported the effect in diabetic rats. This work is why humanin is discussed in metabolism as well as in neuroscience, and it is in rats.

The paper that put humanin into the longevity conversation is from 2020. Pinchas Cohen's group at the University of Southern California pulled together several threads: circulating humanin falls with age in people and in mice; the children of centenarians — people with a family history of unusually long life — had higher humanin than age-matched controls; the naked mole rat, a rodent that lives about ten times longer than a mouse, kept its levels through life; and in the worm C. elegans, expressing humanin extended lifespan ³. Each piece is an association or a worm. Together they make a case that humanin tracks with longevity, which is not the same as causing it, and the authors say so.

There is no clinical trial of humanin in humans, no approved drug based on it, and no published measurement of what giving it to a person does. What exists in people is observational: blood levels measured across ages, in centenarian families, and in conditions such as Alzheimer's disease and coronary disease where levels tend to run lower ²³. Humanin is also unusual among the peptides discussed on this site in that the body makes it, in tissues that include brain, heart, muscle and the gut lining, so the questions researchers are asking are about why its level changes and what that signals, not about replacing something foreign.